Alcon (NYSE:ALC) announced today that it intends to acquire glaucoma surgery device maker Ivantis for $475 million upfront.
Geneva, Switzerland-based Alcon aims to bolster its portfolio across cataract, refractive, retina and glaucoma offerings by acquiring Ivantis and its novel Hydrus Microstent for minimally invasive glaucoma surgery (MIGS).